Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-19-057492

Chief R&D Officer sold 3,960 shares at $17.97 ($71,161)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2019-11-18 Sale : show line 1 in the form −3,960 $17.97 $71,161 291,697 D
Open-market sales · 3,960 sh · avg $17.97 · $71,161
Loading xslF345X03/doc4.xml…